Search Results
Your search for ,UsE matches 11242 pages
Showing 5001 - 5050Pembrolizumab as Third-Line Option for Extensive-Stage Small Cell Lung Cancer
USE OF the anti–programmed cell death protein 1 (anti–PD-1) checkpoint inhibitor pembrolizumab after two or more prior lines of therapy led to responses in patients with advanced small cell lung cancer (SCLC) in a pooled analysis of two clinical trials: phase Ib KEYNOTE-028 and phase II...
AACR Study Presentations Include New Data in Breast and Prostate Cancers, Sarcoma, and High-Risk Individuals
THE 2019 American Association for Cancer Research (AACR) Annual Meeting was held March 29 to April 3 in Atlanta. In addition to our regular coverage of news stories from the meeting, here are some brief highlights of additional noteworthy studies. Stage IV HER2-Positive Breast Cancer: Surgery or No ...
Expert Point of View: Roy S. Herbst, MD, PhD
FORMAL STUDY discussant, Roy S. Herbst, MD, PhD, Chief of Medical Oncology at the Yale Cancer Center, New Haven, Connecticut, stated that the findings of the TATTON analyses are “compelling,” and the combination of osimertinib plus savolitinib can be considered a “win,” although randomized trials...
Osimertinib Plus Savolitinib in Advanced NSCLC Driven by MET Resistance
THE ADDITION of the MET inhibitor savolitinib to the EGFR inhibitor osimertinib led to activity in patients with MET-amplified, EGFR-mutated non–small lung cancer (NSCLC) with acquired resistance to previous therapies, according to interim results from two expansion cohorts of a phase Ib clinical...
Harnessing the Power of Twitter for Clinical Trial Enrollment and Success
CLINICAL TRIALS are vital for advancing cancer care for our patients. Each trial represents an unanswered problem for which researchers are committed to solving. Designing, funding, recruiting, and completing a trial are tremendous undertakings for each researcher, physician, patient, and...
Neoadjuvant Immunotherapy Associated With Improved Outcomes in Patients With Locally Advanced Melanoma
ACCORDING TO DATA from a small prospective study presented at the 2019 Society of Surgical Oncology Annual Cancer Symposium,1 neoadjuvant immunotherapy significantly prolonged relapse-free survival vs adjuvant immunotherapy in patients with stage III or oligometastatic stage IV melanoma intended...
FDA Pipeline: Designations in Triple-Negative Breast Cancer, ctDNA Detection
This week, the U.S. Food and Drug Administration (FDA) granted a Fast Track designation to a treatment for CCR5-positive metastatic triple-negative breast cancer; granted Breakthrough Device designation to a test for the postsurgical detection and quantification of circulating tumor DNA (ctDNA);...
Oropharyngeal Cancer Trends in White Men
In a study reported in the Journal of Clinical Oncology, Tota et al found that there has been a reduction in the increase of oropharyngeal cancer among young white men, with a high number of cases projected among older white men in coming years. As stated by the investigators, “Human...
ASBrS 2019: Opioid Management Program Reduces Post–Breast Surgery Narcotic Use
A breast surgery opioid prescription management program that analyzed current physician patterns and provided education and guidelines successfully reduced the volume of narcotics given postoperatively to patients at a large institution. These results were presented by Fan et al at the Annual...
Treatment-Related Adverse Events With PD-1/PD-L1 Inhibitors in Clinical Trials
In a systematic review and meta-analysis reported in JAMA Oncology, Wang et al characterized treatment-related adverse event profiles associated with monotherapy use of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors in clinical trials. Study Details...
AUA 2019: Insights in Prostate Cancer Identification and Management
Prostate cancer diagnosis and treatment are ever-changing, with new research showcasing different ways to identify and manage patients with the disease. Three new abstracts—highlighting how beta-blockers may impact prostate cancer risk, the advantages and disadvantages of using magnetic...
ESTRO 38: REQUITE Project Finds Predictive Biomarkers for Late Radiotherapy Toxicity
The latest results from the REQUITE project, which aimed to discover what makes patients more likely to experience adverse effects after radiotherapy, have shown that a combination of biologic markers and certain genetic changes can predict radiation sensitivity. In addition, the international team ...
ESTRO 38: High–Dose Rate Brachytherapy in Localized Prostate Cancer
A single high dose of radiation that can be delivered directly to a treatment site within a few minutes is a safe and effective technique for treating men with localized, low-risk prostate cancer, according to a study presented by Tharmalingam et al at ESTRO 38, the annual congress of the ...
FDA Pipeline: Applications and Designations in Prostate Cancer, Leukemia, and HER2-Positive Cancers
In the past 2 weeks, the U.S. Food and Drug Administration (FDA) accepted a new drug application and granted Priority Review for a prostate cancer treatment, granted Orphan Drug designation to a treatment for acute lymphoblastic leukemia, accepted an investigational new drug application for a...
Treat-and-Release Emergency Department Use by Patients With Gynecologic Cancers
In a study reported in the Journal of Oncology Practice, Albright et al found that treat-and-release emergency department use by patients with gynecologic cancers has increased in recent years, with an increase in total cost in this population but not in average visit cost. Visits and Costs...
FDA Approves First-Line Ivosidenib for IDH1-Mutated AML
On May 2, the U.S. Food and Drug Administration (FDA) expanded its approval of ivosidenib (Tibsovo) to include newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that ...
ESMO Breast Cancer 2019: Does Continuous Chemotherapy Benefit Patients With Advanced Breast Cancer?
Continuous chemotherapy showed greater benefit in patients with advanced breast cancer by both improving survival and maintaining quality of life compared to intermittent scheduling, according to analyses of the Stop&Go study presented by Erdkamp et al and Claessens et al at the European...
Psychosocial Care Is a Critical Component of Value-Based Oncology
The ongoing dialogue regarding health-care payment reform that attempts to incentivize high-value care by linking reimbursement to quality rather than quantity has largely ignored the ultimate consumer/buyer—the patient. Yet, in the minds of clinicians, policymakers, and the public at large,...
Adjuvant Capecitabine After Resection for Biliary Tract Cancer
In the phase III BILCAP trial reported in The Lancet Oncology, John N. Primrose, FMedSci, and colleagues found evidence that adjuvant capecitabine may improve overall survival vs observation following surgery for patients with resected biliary tract cancer. The open-label study included 447...
Nobel Laureate and Pioneer in Molecular Biology, Sydney Brenner, MSc, MBBCh, DPhil, Dies at 92
Sydney Brenner, MSc, MBBCh, DPhil, died on April 6, 2019, at age 92, according to The Agency for Science, Technology and Research (A*STAR) in Singapore, where Dr. Brenner had served as a Senior Fellow. Dr. Brenner was conferred the Nobel Prize in Physiology or Medicine in 2002 for his pioneering...
FDA Oncology Center of Excellence Issues Annual Report
The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) has issued its 2018 Annual Report,1 including updates on regulatory reviews and initiatives, OCE programs, guidances, and more. The OCE is tasked with clinical medical oncology reviews, irrespective of whether the...
FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma
On April 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to erdafitinib (Balversa) for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations that has progressed during or following platinum-containing...
Local Consolidative Therapy Linked to Survival Benefit in Oligometastatic Non–Small Cell Lung Cancer
A retrospective analysis of nearly 200 patients treated with local consolidative therapy for oligometastatic non–small cell lung cancer (NSCLC) has found improved overall survival associated with aggressive consolidation.1 According to data presented at the 2019 Multidisciplinary Thoracic Cancers...
ESMO Breast Cancer 2019: ONCOLLEGE-001: Global Survey of HER2 Testing
A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2-targeted therapies for breast cancer, especially in lower-income countries. These results will be presented at the European Society for Medical Oncology (ESMO) Breast Cancer...
Final Overall Survival Analysis of the LATITUDE Trial in Newly Diagnosed, High-Risk, Metastatic, Castration-Sensitive Prostate Cancer
As reported in The Lancet Oncology by Fizazi et al, the final overall survival analysis in the phase III LATITUDE trial has shown a significant benefit with the addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) in newly diagnosed, high-risk, metastatic, ...
Colon Cancer Proteogenomic Analysis May Uncover New Potential Treatments
A new study analyzing the entire set of genes and all the proteins produced by colon cancer tissues from patient samples has revealed a more comprehensive view of the tumor, pointing to novel cancer biologic mechanisms and possible new therapeutic strategies. This multidisciplinary and...
New Biomarkers Associated With Cancer-Related Cognitive Impairment Identified
Cognitive impairment associated with cancer—also known as “chemobrain”—has gained recognition as a complication of the disease and its treatment. With this in mind, a research team started to investigate levels of biomarkers in relation to chemobrain to better understand its ...
Intermittent vs Intensive PEG-Asparaginase in Pediatric Acute Lymphoblastic Leukemia
In a Scandinavian study reported in the Journal of Clinical Oncology, Albertsen et al found that use of intermittent vs intensive pegylated (PEG)-asparaginase was associated with similar efficacy and reduced asparaginase-related toxicity in pediatric acute lymphoblastic leukemia (ALL). The study...
Ramucirumab After Sorafenib in Advanced Hepatocellular Carcinoma: An Efficacious Therapy With Applicability Challenges
In the 2 years since the U.S. Food and Drug Administration’s (FDA) approval of regorafenib in the treatment of patients with sorafenib-refractory advanced hepatocellular carcinoma, we oncologists have witnessed a veritable avalanche of newly approved medicines for the treatment of advanced...
Ramucirumab in Sorafenib-Pretreated Patients With Advanced Hepatocellular Carcinoma
In the phase III REACH-2 trial reported in The Lancet Oncology, Andrew X. Zhu, MD, of Harvard Medical School and Massachusetts General Hospital, and colleagues found that ramucirumab improved overall and progression-free survival vs placebo in patients with advanced hepatocellular carcinoma and...
Expert Point of View: Rafael Fonseca, MD
Rafael Fonseca, MD, the Getz Family Professor of Cancer and Chair of the Department of Medicine, Mayo Clinic in Arizona and an expert in minimal residual disease (MRD) in myeloma, commented on the PRIMeR study for The ASCO Post. The PRIMeR subanalysis of the STaMINA trial showed the prognostic...
Ryan C. Fields, MD, Named Chief of Surgical Oncology at Washington University in St. Louis
Ryan C. Fields, MD, has been named Chief of the Section of Surgical Oncology at Washington University School of Medicine in St. Louis. Dr. Fields, who joined the faculty in 2011, is also Associate Professor of Surgery, Associate Program Director of the General Surgery Residency Program, and...
Preliminary Results Show Activity for Mesothelin‑Directed CAR T-Cell Therapy in Malignant Mesothelioma
A phase I clinical trial showed encouraging results with chimeric antigen receptor (CAR) T-cell therapy targeted to the mesothelin protein in patients with mesothelin-associated malignant pleural solid tumors—primarily, malignant mesothelioma—that had progressed following standard platinum-based...
Expert Point of View: Charles B. Simone II, MD, and Aaron S. Mansfield, MD
In a press briefing before the 2019 Multidisciplinary Thoracic Cancers Symposium, Charles B. Simone II, MD, a radiation oncologist and Chief Medical Officer at the New York Proton Center, noted that although the National Comprehensive Cancer Network® (NCCN®) provides high-quality clinical...
Online Tool May Improve Guideline Concordance for Patients With Lung Cancer
An online tool that allows patients to input their clinical and pathologic features as well as explore treatment options in a structured manner based on National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines) may help drive smoking cessation and testing for ...
Expert Point of View: Kristin Higgins, MD
The discussant of the abstract on repeat positron-emission tomography (PET) and/or computed tomography (CT) scans prior to chemoradiation in locally advanced non–small cell lung cancer, Kristin Higgins, MD, emphasized the importance of timing of imaging when staging patients and the need for...
Role of Repeat PET/CT Scans in Ensuring Accuracy of Staging of Locally Advanced NSCLC
Findings from a new study highlight the importance of timing in initial staging positron-emission tomography (PET) and/or computed tomography (CT) scans for patients with locally advanced non–small cell lung cancer (NSCLC) receiving chemoradiation therapy.1 According to data presented at the 2019...
Mitigating Frailty and Sarcopenia to Improve Treatment Outcomes in Lung Cancer
Frailty and sarcopenia are common conditions among patients with lung cancer and are linked with decreased survival as well as increased surgical complications, chemotherapy toxicity, and cost of care. If a survey of oncologists at the 2019 Multidisciplinary Thoracic Cancers Symposium is any...
DNA Rearrangement May Predict Treatment Resistance and Poor Outcomes in Multiple Myeloma
A certain type of DNA marker may predict poor outcomes in multiple myeloma, researchers at Winship Cancer Institute of Emory University have found. The marker is a particular rearrangement of chromosomes that is rarely tested for but may indicate resistance to immunomodulatory drugs such as...
Does Oncotype DX–Guided Treatment Reduce Initial Costs of Breast Cancer Care?
A new study suggests that Oncotype DX–guided treatment could reduce the cost for the first year of breast cancer care in the United States by about $50 million (about 2% of the overall costs in the first year). These findings were published by Mariotto et al in the Journal of the...
Combined Crowd Innovation and AI in Producing Algorithms for Radiotherapy Targeting
In a study reported in JAMA Oncology, Mak et al found that a crowd innovation contest produced automated artificial intelligence (AI) algorithms “that replicated the skills of a highly trained physician” in segmenting lung tumors for radiotherapy targeting. The investigators also noted...
Low-Dose Tamoxifen vs Placebo in Preventing Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
In an Italian phase III study reported in the Journal of Clinical Oncology, DeCensi et al found that tamoxifen at 5 mg/d vs placebo for 3 years reduced the risk of recurrence of breast intraepithelial neoplasia and was associated with limited toxicity. As noted by the investigators,...
Dance/Movement Therapy: Getting to Feelings That Have No Words
Dance/movement therapy is a complementary modality that is being explored for symptom control and for improving the quality of life of patients with cancer, especially pediatric patients. Self-expression as well as the creative and interpersonal aspects of dance/movement therapy can help patients...
The Evolving Role of Pathologists in the Diagnosis and Treatment of Cancer
In the past, the role of the pathologist was primarily to present anatomic pathology findings on various specimens, particularly at tumor boards. However, in the emerging age of personalized medicine and molecular diagnostics, the responsibilities of pathologist have greatly expanded into...
New Model May Improve Prediction of Risk in Myelodysplastic Syndromes
A PERSONALIZED risk-prediction model for myelodysplastic syndromes (MDS) has been developed through the use of a machine-learning approach that analyzes genomic and clinical data for an individual patient. According to lead investigator Aziz Nazha, MD, of the Cleveland Clinic, the model provides...
Expert Point of View: Aaron S. Mansfield, MD
The discussant of the STELLAR trial abstract, Aaron S. Mansfield, MD, a translational scientist at the Mayo Clinic in Rochester, called the survival outcomes “very promising” for a trial that included a relatively large population of patients with the more aggressive sarcomatoid variant of...
Robert A. Kyle, MD, Luminary in Myeloma Research: Journey From a One-Room Schoolhouse to Groundbreaking Research
In this installment of Living a Full Life, guest editor Jame Abraham, MD, FACP, interviewed multiple myeloma pioneer Robert A. Kyle, MD, whose groundbreaking work has changed the practice of hematology. Among his many honors are the David A. Karnofsky Memorial Award from ASCO and the Wallace H....
Tumor-Treating Fields Plus Chemotherapy Improved Survival in Unresectable Malignant Pleural Mesothelioma
The addition of tumor-treating fields to standard-of-care chemotherapy has been found to be safe and effective in the treatment of unresectable malignant pleural mesothelioma. Data presented at the 2019 Multidisciplinary Thoracic Cancers Symposium showed that patients receiving the combination of...
Colonoscopy Polyp Detection Rates and Endoscopist Characteristics
Previous research has suggested that specific factors about the doctor performing colonoscopy—for example, a gastroenterologist vs a surgeon, female vs male—were associated with different rates of detection of precancerous polyps. However, a Cleveland Clinic–led research team...
Shared Decision-Making in Lung Cancer Screening: Whence? Whither?
We read with interest a recent article published on ASCOPost.com, which summarized a paper on the role of shared decision-making in lung cancer screening.1,2 The summary and original report highlight a mandate by the Centers for Medicare & Medicaid Services (CMS) that bears careful...
